Skip To Main Content

Cell Therapies for Life-Threatening Diseases

About Our Science Pipeline

The Unmet Needs

LyGenesis’s cell therapies are targeted at some of the largest unmet needs in medicine, from Type 1 diabetes to end stage liver and renal disease.

Our cell therapies completely upend the economics and supply-demand calculus of organ transplantation by using the patient’s own lymph nodes as bioreactors to grow functioning ectopic organs. For our lead liver indication, one donated liver can treat dozens of ESLD patients, and the cell therapy is engrafted into the lymph nodes using an outpatient endoscopic ultrasound procedure, which is associated with substantially decreased medical risks and costs relative to full organ transplantation.

to see how LyGenesis's pioneering cell therapies enable organ regeneration.
THYMUS LIVER KIDNEYS PANCREAS

Our Pipeline

Discovery
Small Animal
Large Animal
Phase 1
Phase 2
Phase 3
FDA Approval
  • Liver
    End Stage Liver Disease
    Phase 2A
  • Thymus
    Aging
    POC Completed
  • Kidneys
    End Stage Renal Disease
    POC Completed
  • Pancreas
    Type 1 Diabetes
    POC Completed

LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs.

stock image of scientists in lab coats and gloves

Revolutionary Biotechnology

Our allogeneic cell therapies leverage the biology of the lymph node to engraft, proliferate, and form functional ectopic organs that recapitulate the native organ’s function.